Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

Clinical trial NCT02113982 · COMPLETED

Trial details

NCT number: NCT02113982
Sponsor: Stemline Therapeutics, Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Acute Myeloid Leukemia (AML)

Start date: 2014-09-01
Primary completion: 2020-02-01
Enrollment: 138

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.